← Back to patent-cliff list
SYL-1801
Tier C — Watch / tradeSYL-1801
Sylentis Sa
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Nucleic acid drug
Type
Targets：NRARP
Indications (approved)：年龄相关性黄斑变性, 湿性年龄相关性黄斑变性, 脉络膜新生血管化, Glaucoma
Regional status
US
-
EU
Phase II
2022-11-22
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of SYL-1801?
Approved indications include: 年龄相关性黄斑变性, 湿性年龄相关性黄斑变性, 脉络膜新生血管化, Glaucoma.
When does the SYL-1801 patent expire?
No public expiry year is available for SYL-1801 yet; this page updates once verified.
How do I get a quote for SYL-1801 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-03